Tsurutani Junji 鶴谷純司

… Alternative Names

鶴谷純司ツルタニジュンジ

TSURUTANI Junji 鶴谷純司

Less

Researcher Number	30319686
Other IDs	https://orcid.org/0000-0002-6260-6943
Affiliation (Current)	2024: 昭和大学, 大学共同利用機関等の部局等, 教授
Affiliation (based on the past Project Information) *help	2019 – 2022: 昭和大学, 大学共同利用機関等の部局等, 教授 2014 – 2016: 近畿大学, 医学部, 准教授
Review Section/Research Field	Principal Investigator Basic Section 50010:Tumor biology-related / Tumor therapeutics Except Principal Investigator Basic Section 58060:Clinical nursing-related
Keywords	Principal Investigator 薬剤耐性 / 乳癌 / 上皮間葉移行 / 腫瘍進展 / 肺癌 / 上皮間葉転換 / 難治性腫瘍 / 葉酸受容体 / 分子標的治療 / heregulin … More / 血漿検体 / SKBR-3 / N87 / cfDNA BC / WJOG7212G / 西日本がん研究機構 / ヘレギュリン / 分子標的薬 / 化学療法 / 胃癌 / HER2 … More Except Principal Investigator 乳がん患者 / 化学療法誘発性末梢神経障害 / ハンドセラピー施術 / 抗癌剤副作用 / 化学療法誘発性末梢神経障害CIPN / しびれ改善 / 対処療法 / 化学療法末梢性神経障害(CIPN) / 血行促進 / ハンドセラピー / 化学療法誘発性末梢神経障害（CIPN） / 抗がん剤副作用 / 乳がん Less

To investigate mechanisms and a role of folate receptor induction in tumor developmentPrincipal Investigator
- Principal Investigator
  
  鶴谷純司
- Project Period (FY)
  2022 – 2024
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 50010:Tumor biology-related
- Research Institution
  Showa University
Establishment of hand therapy technique to improve numbness symptoms after chemotherapy for breast cancer patients
- Principal Investigator
  
  Sasaki Akiko
- Project Period (FY)
  2019 – 2022
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 58060:Clinical nursing-related
- Research Institution
  Showa University
A biomarker study of heregulin to predict efficacy of anti-HER2 drugs in HER2-positive breast and gastric cancerPrincipal Investigator
- Principal Investigator
  
  TSURUTANI Junji
- Project Period (FY)
  2014 – 2016
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Tumor therapeutics
- Research Institution
  Kindai University

All 2022 2021 2020 2019 2018 2017 2016 2014

All Journal Article Presentation Book

[Book] 乳腺腫瘍学2022
- Author(s)
  鶴谷純司
- Total Pages
  4
- Publisher
  金原出版株式会社
- Data Source
  KAKENHI-PROJECT-22K07216
[Book] 乳癌診療2022
- Author(s)
  鶴谷純司
- Total Pages
  3
- Publisher
  医歯薬出版株式会社
- Data Source
  KAKENHI-PROJECT-22K07216
[Book] がん免疫ペディア2022
- Author(s)
  鶴谷純司
- Total Pages
  3
- Publisher
  羊土社
- Data Source
  KAKENHI-PROJECT-22K07216
[Book] 新臨床腫瘍学改訂第4版2017
- Author(s)
  鶴谷純司
- Total Pages
  840
- Publisher
  南江堂
- Data Source
  KAKENHI-PROJECT-26430174
[Journal Article] Mechanisms of EGFR-TKI-Induced Apoptosis and Strategies Targeting Apoptosis in EGFR-Mutated Non-Small Cell Lung Cancer2022
- Author(s)
  Nishihara Shigetoshi、Yamaoka Toshimitsu、Ishikawa Fumihiro、Higuchi Kensuke、Hasebe Yuki、Manabe Ryo、Kishino Yasunari、Kusumoto Sojiro、Ando Koichi、Kuroda Yusuke、Ohmori Tohru、Sagara Hironori、Yoshida Hitoshi、Tsurutani Junji
- Journal Title
  
  Genes
  
  Volume: 13 Issue: 12 Pages: 2183-2183
- DOI
  10.3390/genes13122183
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-22K07216
[Journal Article] Data of programmed death-ligand 1 expression and VEGF: Nivolumab, bevacizumab and paclitaxel For HER2-negative metastatic breast cancer2022
- Author(s)
  Ozaki Yukinori、Tsurutani Junji、Mukohara Toru、Iwasa Tsutomu、Takahashi Masato、Tanabe Yuko、Kawabata Hidetaka、Masuda Norikazu、Futamura Manabu、Minami Hironobu、Matsumoto Koji、Yoshimura Kenichi、Kitano Shigehisa、Takano Toshimi
- Journal Title
  
  Data in Brief
  
  Volume: 45 Pages: 108558-108558
- DOI
  10.1016/j.dib.2022.108558
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-22K07216
[Journal Article] Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B)2022
- Author(s)
  Ozaki Yukinori、Tsurutani Junji、Mukohara Toru、Iwasa Tsutomu、Takahashi Masato、Tanabe Yuko、Kawabata Hidetaka、Masuda Norikazu、Futamura Manabu、Minami Hironobu、Matsumoto Koji、Yoshimura Kenichi、Kitano Shigehisa、Takano Toshimi
- Journal Title
  
  European Journal of Cancer
  
  Volume: 171 Pages: 193-202
- DOI
  10.1016/j.ejca.2022.05.014
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-22K07216, KAKENHI-PROJECT-20K07676
[Journal Article] Morphine Versus Oxycodone for Cancer Pain Using a Catechol-O-methyltransferase Genotype Biomarker: A Multicenter, Randomized, Open-Label, Phase III Clinical Trial (RELIEF Study)2022
- Author(s)
  Matsuoka Hiromichi、Tsurutani Junji、Chiba Yasutaka、Fujita Yoshihiko、Sakai Kiyohiro、Yoshida Takeshi、Nakura Miki、Sakamoto Ryo、Makimura Chihiro、Ohtake Yoichi、Tanaka Kaoru、Hayashi Hidetoshi、Takeda Masayuki、Okuno Tatsuya、Takegawa Naoki、Haratani Koji、Koyama Atsuko、Nishio Kazuto、Nakagawa Kazuhiko
- Journal Title
  
  The Oncologist
  
  Volume: 28 Issue: 3 Pages: 278-e166
- DOI
  10.1093/oncolo/oyac233
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-22K07216
[Journal Article] Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an EGFR-Activating Mutation2022
- Author(s)
  Nishihara Shigetoshi、Yamaoka Toshimitsu、Ishikawa Fumihiro、Ohmori Tohru、Ando Koichi、Kusumoto Sojiro、Kishino Yasunari、Manabe Ryo、Hasebe Yuki、Sagara Hironori、Yoshida Hitoshi、Tsurutani Junji
- Journal Title
  
  Cells
  
  Volume: 11 Issue: 14 Pages: 2201-2201
- DOI
  10.3390/cells11142201
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-22K07216
[Journal Article] 化学療法誘発性末梢神経障害を有する乳がん患者に対するハンドセラピー施術後の改善効果の検討2020
- Author(s)
  佐々木晶子、池田明子、角田ゆう子、沢田晃暢、鶴谷純司、辰尾秋斗、木内祐二、中村清吾
- Journal Title
  
  癌と化学療法
  
  Volume: 47 Pages: 783788-783788
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-19K10886
[Journal Article] Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer2019
- Author(s)
  Satomi Watanabe, Kimio Yonesaka, Junko Tanizaki, Yoshikane Nonagase, Naoki Takegawa, Koji Haratani, Hisato Kawakami, Hidetoshi Hayashi, Masayuki Takeda, Junji Tsurutani, Kazuhiko Nakagawa
- Journal Title
  
  Cancer Medicine
  
  Volume: 8 Issue: 3 Pages: 1258-1268
- DOI
  10.1002/cam4.1995
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-26430174
[Journal Article] [fam‐] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification2019
- Author(s)
  Takegawa Naoki、Tsurutani Junji、Kawakami Hisato、Yonesaka Kimio、Kato Ryoji、Haratani Koji、Hayashi Hidetoshi、Takeda Masayuki、Nonagase Yoshikane、Maenishi Osamu、Nakagawa Kazuhiko
- Journal Title
  
  International Journal of Cancer
  
  Volume: 145 Issue: 12 Pages: 3414-3424
- DOI
  10.1002/ijc.32408
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-19K11730, KAKENHI-PROJECT-26430174
[Journal Article] Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer2018
- Author(s)
  Satomi Watanabe, Hidetoshi Hayashi, Koji Haratani, Shigeki Shimizu, Junko Tanizaki, Kazuko Sakai, Hisato Kawakami, Kimio Yonesaka, Junji Tsurutani, Yosuke Togashi, Kazuto Nishio, Akihiko Ito, Kazuhiko Nakagawa
- Journal Title
  
  Cancer Science
  
  Volume: 110 Issue: 1 Pages: 52-60
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-26430174
[Journal Article] HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer.2018
- Author(s)
  Sakai H, Tsurutani J, Iwasa T, Komoike Y, Sakai K, Nishio K, Nakagawa K.
- Journal Title
  
  Breast Cancer
  
  Volume: 25(5) Issue: 5 Pages: 605-613
- DOI
  10.1007/s12282-018-0861-9
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PLANNED-17H06404, KAKENHI-PROJECT-26430174
[Journal Article] DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance2017
- Author(s)
  Naoki Takegawa, Yoshikane Nonagase, Kimio Yonesaka, Kazuko Sakai, Osamu Maenishi, Yusuke Ogitani, Takao Tamura, Kazuto Nishio, Kazuhiko Nakagawa, Junji Tsurutani
- Journal Title
  
  International Journal of Cancer
  
  Volume: 141 Issue: 8 Pages: 1682-1689
- DOI
  10.1002/ijc.30870
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-26430174
[Journal Article] Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1.2016
- Author(s)
  Nonagase Y, Yonesaka K, Kawakami H, Watanabe S, Haratani K, Takahama T, Takegawa N, Ueda H, Tanizaki J, Hayashi H, Yoshida T, Takeda M, Chiba Y, Tamura T, Nakagawa K, Tsurutani J.
- Journal Title
  
  Oncotarget
  
  Volume: 20;7(51) Issue: 51 Pages: 84860-84871
- DOI
  10.18632/oncotarget.12743
- Peer Reviewed / Acknowledgement Compliant / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-26430174
[Journal Article] HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer2016
- Author(s)
  Naoki Takegawa, Kimio Yonesaka, Kazuko Sakai, Hiroto Ueda, Satomi Watanabe, Yoshikane Nonagase, Tatsuya Okuno, Masayuki Takeda, Osamu Maenishi, Junji Tsurutani, Taroh Satoh, Isamu Okamoto, Kazuto Nishio, Takao Tamura, Kazuhiko Nakagawa
- Journal Title
  
  Oncotarget
  
  Volume: 7 Issue: 3 Pages: 3453-3460
- DOI
  10.18632/oncotarget.6498
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-26430174
[Journal Article] Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines.2014
- Author(s)
  Terashima M, Sakai K, Togashi Y, Hayashi H, De Velasco MA, Tsurutani J, Nishio K.
- Journal Title
  
  Springerplus
  
  Volume: 3 Issue: 1 Pages: 417-417
- DOI
  10.1186/2193-1801-3-417
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-24240122, KAKENHI-PROJECT-26430174
[Presentation] P1-12-08Biomarker analysis of hepatotoxicity in a phase II study of nivolmab, abemaciclib and endocrine therapy in pts with HR-positive, HER2-negative breast cancer: NEWFLAME TR2022
- Author(s)
  Junji Tsurutani , Jun Masuda, Norikazu Masuda, Yuko Tanabe, Tsutomu Iwasa, Masato Takahashi, Manabu Futamura, Koji Matsumoto, Kenjiro Aogi, Hiroji Iwata, Mari Hosonaga, Toru Mukohara, Kiyoshi Yoshimura, Chiyo Imamura, Sakiko Miura, Toshiko Yamochi, Kenichi Yoshimura, Hidetaka Kawabata, and Toshimi Takano
- Organizer
  San Antonio Breast Cancer Symposium
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-22K07216
[Presentation] EP17-4　Phase II study of olanzapine for CINV during T-DXd in HER2+ mBC patients: WJOG14320B(ERICA)2022
- Author(s)
  Hitomi Sakai, Junji Tsurutani, Takamichi Yokoe, Chiyo K Imamura, Koji Matsumoto, Tsutomu Iwasa, Yasutaka Chiba, Yuji Hirakawa and Toshimi Takano
- Organizer
  第30回日本乳癌学会学術総会
- Data Source
  KAKENHI-PROJECT-22K07216
[Presentation] 肺腺癌細胞PC-9におけるオシメルチニブの獲得耐性機序の検討2022
- Author(s)
  山岡利光, 長谷部友紀, 眞鍋亮, 楠本壮二郎, 安藤浩一, 相良博典, 鶴谷純司.
- Organizer
  第63回日本肺癌学会学術集会
- Data Source
  KAKENHI-PROJECT-22K07216
[Presentation] Resistance mechanisms against osimertinib in lung adenocarcinoma cells with EGFR-activating mutation2022
- Author(s)
  Nishihara S, Yamaoka T, Tsurutani J, et al.
- Organizer
  第８１回日本癌学会学術総会
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-22K07216
[Presentation] 肺腺癌細胞におけるオシメルチニブの獲得耐性機序の検討2022
- Author(s)
  西原成俊, 山岡利光, 長谷部友紀, 石川文博, 楠本壮二郎, 大森亨, 相良博典, 鶴谷純司, 吉田仁.
- Organizer
  第69回昭和大学学士会総会
- Data Source
  KAKENHI-PROJECT-22K07216
[Presentation] ハンドセラピー施術と冷却法併用による CIPNのしびれ改善方法2021
- Author(s)
  佐々木晶子, 垂野香苗, 鶴谷純司, 和泉麻里子, 中村清吾
- Organizer
  第59回日本癌治療学会学術総会
- Data Source
  KAKENHI-PROJECT-19K10886
[Presentation] heregulin発現HER2陽性乳癌・胃癌における抗HER2薬ラパチニブ、トラスツズマブ、T-DM1の感受性に関する研究2017
- Author(s)
  野長瀬祥兼, 米阪仁雄, 川上尚人, 渡邉諭美, 原谷浩司, 高濱隆幸, 武川直樹, 植田勲人, 谷崎潤子, 林秀敏, 吉田健史, 武田真幸, 千葉康敬, 田村孝雄, 中川和彦, 鶴谷純司
- Organizer
  第25回日本乳癌学会総会
- Data Source
  KAKENHI-PROJECT-26430174
[Presentation] T-DM1 de novo 耐性HER2陽性乳癌の臨床病理学的検討2017
- Author(s)
  酒井瞳, 岩朝勤, 菰池佳史, 鶴谷純司, 坂井和子, 西尾和人, 中川和彦
- Organizer
  第25回日本乳癌学会総会
- Data Source
  KAKENHI-PROJECT-26430174
[Presentation] Heregulin-induced resisitance agatinst HER2-targeted therapies in HER2-positive breast cancer and gastric cancer in vitro and in vivo2016
- Author(s)
  Nonagase Y, Tsurutani J, et al.
- Organizer
  American Association for Cancer Reserch
- Place of Presentation
  Ernest N. Morial Convention Center(米国、ニューオリンズ)
- Year and Date
  2016-04-16
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-26430174
[Presentation] Heregulin-induced resisitance agatinst HER2-targeted therapies in HER2-positive breast cancer and gastric cancer in vitro and in vivo20162016
- Author(s)
  Yoshikane Nonagase, Junji Tsurutani, et al.
- Organizer
  Annual meeting, American Association of Cancer Research双方修正にて加筆(11/16昭和大学松山様)
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-26430174
[Presentation] 乳腺個別化医療を拓くバイオマーカー研究HER2陽性乳癌個別化治療の近未来-双方修正にて加筆(11/16昭和大学松山様)2016
- Author(s)
  鶴谷純司
- Organizer
  第24回日本乳癌学会総会
- Invited
- Data Source
  KAKENHI-PROJECT-26430174

1. Sasaki Akiko (10398688)

# of Collaborated Projects: 1 results

# of Collaborated Products: 2 results
2. 中川和彦 (40298964)

# of Collaborated Projects: 1 results

# of Collaborated Products: 7 results
3. 米阪仁雄 (30330260)

# of Collaborated Projects: 1 results

# of Collaborated Products: 6 results
4. 中村清吾 (70439511)

# of Collaborated Projects: 1 results

# of Collaborated Products: 2 results
5. 沢田晃暢 (80266105)

# of Collaborated Projects: 1 results

# of Collaborated Products: 1 results
6. 前西修

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
7. 西尾和人

# of Collaborated Projects: 0 results

# of Collaborated Products: 2 results
8. 坂井和子

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results

Tsurutani Junji 鶴谷 純司

鶴谷 純司 ツルタニ ジュンジ

TSURUTANI Junji 鶴谷 純司

Research Projects

Research Products

Co-Researchers

To investigate mechanisms and a role of folate receptor induction in tumor developmentPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Establishment of hand therapy technique to improve numbness symptoms after chemotherapy for breast cancer patients

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

A biomarker study of heregulin to predict efficacy of anti-HER2 drugs in HER2-positive breast and gastric cancerPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

[Book] 乳腺腫瘍学2022

Author(s)

Total Pages

Publisher

Data Source

[Book] 乳癌診療2022

Author(s)

Total Pages

Publisher

Data Source

[Book] がん免疫ペディア2022

Author(s)

Total Pages

Publisher

Data Source

[Book] 新臨床腫瘍学 改訂第4版2017

Author(s)

Total Pages

Publisher

Data Source

[Journal Article] Mechanisms of EGFR-TKI-Induced Apoptosis and Strategies Targeting Apoptosis in EGFR-Mutated Non-Small Cell Lung Cancer2022

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Data of programmed death-ligand 1 expression and VEGF: Nivolumab, bevacizumab and paclitaxel For HER2-negative metastatic breast cancer2022

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B)2022

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Morphine Versus Oxycodone for Cancer Pain Using a Catechol-O-methyltransferase Genotype Biomarker: A Multicenter, Randomized, Open-Label, Phase III Clinical Trial (RELIEF Study)2022

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an EGFR-Activating Mutation2022

Author(s)

Journal Title

DOI

Data Source

[Journal Article] 化学療法誘発性末梢神経障害を有する乳がん患者に対するハンドセラピー施術後の改善効果の検討2020

Author(s)

Journal Title

Data Source

[Journal Article] Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer2019

Author(s)

Journal Title

DOI

Data Source

[Journal Article] [fam‐] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification2019

Author(s)

Tsurutani Junji 鶴谷純司

鶴谷純司ツルタニジュンジ

TSURUTANI Junji 鶴谷純司

[Book] 新臨床腫瘍学改訂第4版2017

[Presentation] EP17-4　Phase II study of olanzapine for CINV during T-DXd in HER2+ mBC patients: WJOG14320B(ERICA)2022